Intra-Cellular Therapies's market cap is currently ―. The company's EPS TTM is $-1.458; its P/E ratio is -50.76; Intra-Cellular Therapies is scheduled to report earnings on May 8, 2024, and the estimated EPS forecast is $-0.32. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	$ 126.17M	$ 110.13M	$ 95.31M	$ 87.87M	$ 71.87M
Gross Profit	$ 126.17M	$ 110.79M	$ 95.31M	$ 87.87M	$ 66.02M
EBIT	$ -24.21M	$ -42.65M	$ -44.04M	$ -47.41M	$ -55.63M
EBITDA	$ -26.27M	$ -44.46M	$ -45.65M	$ -46.10M	$ -55.46M
Net Income Common Stockholders	$ -6.00M	$ -42.78M	$ -44.05M	$ -44.03M	$ -53.51M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 493.02M	$ 514.60M	$ 540.46M	$ 593.65M	$ 628.74M
Total Assets	$ 717.66M	$ 713.60M	$ 720.38M	$ 754.78M	$ 782.00M
Total Debt	$ 17.48M	$ 17.99M	$ 18.49M	$ 20.04M	$ 26.41M
Net Debt	$ -475.55M	$ -496.61M	$ -521.97M	$ -573.61M	$ -602.33M
Total Liabilities	$ 116.98M	$ 106.51M	$ 94.55M	$ 754.78M	$ 96.58M
Stockholders Equity	$ 600.68M	$ 607.09M	$ 627.61M	$ 656.07M	$ 685.42M
Cash Flow	-
Free Cash Flow	$ -25.54M	$ -36.80M	$ -60.07M	$ -39.16M	$ -53.47M
Operating Cash Flow	$ -25.27M	$ -36.80M	$ -60.07M	$ -39.19M	$ -53.35M
Investing Cash Flow	$ -20.17M	$ 94.75M	$ -16.46M	$ 50.26M	$ 106.17M
Financing Cash Flow	$ 2.58M	$ 8.59M	$ 3.64M	$ 2.19M	$ 5.65M

Currency in USD

Intra-Cellular Therapies Earnings and Revenue History

Income Statement >

Intra-Cellular Therapies Debt to Assets

Balance Sheet >

Intra-Cellular Therapies Cash Flow

Cash Flow >

Intra-Cellular Therapies Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing